Journal of Dermatological Science
Volume 59, Issue 1 , Pages 40-49 , July 2010

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

  • Hideshi Torii

      Affiliations

    • Division of Dermatology, Social Insurance Central General Hospital, 3-22-1 Hyakunincho, Shinjyuku, Tokyo 169-0073, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 3 3364 0251; fax: +81 3 3364 5663.
    • ,
  • Hidemi Nakagawa

      Affiliations

    • Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan
    • ,
  • the Japanese Infliximab Study investigators

      Affiliations

    • Investigators for the Japanese Infliximab Study include: H Iizuka, Hokkaido; S Aoyagi, Hokkaido; R Okuyama, Miyagi; M Ohtsuki, Tochigi; M Abe, Gunma; K Takamori, S Matsuba, Chiba; T Terui, Tokyo; A Igarashi, Tokyo; M Kawashima, Tokyo; M Amagai, Y Takae, Tokyo; H Eto, Tokyo; T Etoh, Tokyo; S Ikeda, Tokyo; M Komine, H Saeki, Tokyo; K Hayakawa, Tokyo; A Kitami, H Watanabe, Tokyo; K Takehara, Ishikawa; S Shimada, Yamanashi; Y Kitajima, Gifu; M Takigawa, Shizuoka; A Morita, Aichi; K Yamanaka, Mie; K Takahashi, Kyoto; M Tarutani, M Tani, Osaka; Y Kubota, Kagawa; J Nakayama, Fukuoka; H Ihn, Kumamoto.

Received 1 February 2010 ,Revised 5 April 2010 ,Accepted 24 April 2010.

References 

  1. Bonifati C, Carducci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients—relationships with disease severity. Clin Exp Dermatol. 1994;19:383–387
  2. Mussi A, Bonifati C, Carducci M, D’Agosto G, Pimpinelli F, D’Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11:115–118
  3. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24:518–523
  4. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544–1552
  5. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374
  6. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(31):e1–e15
  7. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou Bei , et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial. IMPACT. 2008;35:869–876
  8. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157
  9. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–194
  10. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:314–321
  11. Tsunemi Y, Nishibu A, Saeki H, Oyama N, Nakamura K, Kishimoto M, et al. Lack of association between the promoter polymorphisms at positions −308 and −238 of the tumor necrosis factor alpha gene and psoriasis vulgaris in Japanese patients. Dermatology. 2003;207:371–374
  12. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157:238–244
  13. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evalution of nail psoriasis. J Am Acad Dermatol. 2003;49:206–212
  14. Pincus T, Summey JA, Soraci SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Standford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346–1353
  15. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–735
  16. Khilji FA, Gonzales M, Finlay AY. Clinical meaning of change in dermatology life quality index scores. Br J Dermatol. 2002;147(Suppl. 62):50
  17. Bedini C, Nasorri F, Girolomoni G, Pità O, Cavani A. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol. 2007;157:249–258
  18. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175(4):2721–2729
  19. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–3194
  20. Ortega C, Fernández AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009; 86:435–43.

PII: S0923-1811(10)00135-0

doi: 10.1016/j.jdermsci.2010.04.014

Journal of Dermatological Science
Volume 59, Issue 1 , Pages 40-49 , July 2010

Article Tools

* Image Usage & Resolution